Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rhabdoid Tumor | 12 | 2023 | 212 | 3.130 |
Why?
|
Brain Neoplasms | 39 | 2024 | 8829 | 1.810 |
Why?
|
Central Nervous System Neoplasms | 13 | 2023 | 895 | 1.550 |
Why?
|
Medulloblastoma | 8 | 2023 | 681 | 1.520 |
Why?
|
Glioma | 23 | 2023 | 3388 | 1.340 |
Why?
|
Cerebellar Neoplasms | 6 | 2023 | 585 | 1.320 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 7 | 2022 | 484 | 1.230 |
Why?
|
Neuroectodermal Tumors, Primitive | 3 | 2022 | 140 | 1.200 |
Why?
|
Brain Stem Neoplasms | 7 | 2022 | 204 | 0.830 |
Why?
|
Teratoma | 4 | 2023 | 387 | 0.670 |
Why?
|
Germinoma | 4 | 2022 | 133 | 0.640 |
Why?
|
Ependymoma | 6 | 2021 | 333 | 0.640 |
Why?
|
Chromosomal Proteins, Non-Histone | 4 | 2022 | 730 | 0.570 |
Why?
|
Neuroblastoma | 4 | 2017 | 1225 | 0.520 |
Why?
|
Taxoids | 1 | 2018 | 665 | 0.500 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2018 | 623 | 0.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 11472 | 0.470 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 9185 | 0.460 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 535 | 0.460 |
Why?
|
Purines | 1 | 2017 | 593 | 0.460 |
Why?
|
Aminopyridines | 1 | 2017 | 541 | 0.450 |
Why?
|
Child | 65 | 2024 | 77478 | 0.450 |
Why?
|
Child, Preschool | 42 | 2023 | 40955 | 0.420 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 670 | 0.420 |
Why?
|
Pyrimidinones | 3 | 2020 | 370 | 0.330 |
Why?
|
Medical Oncology | 3 | 2019 | 2235 | 0.300 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 39 | 0.280 |
Why?
|
Pyridones | 3 | 2020 | 712 | 0.280 |
Why?
|
Maximum Tolerated Dose | 3 | 2018 | 891 | 0.270 |
Why?
|
Adolescent | 41 | 2024 | 85649 | 0.260 |
Why?
|
Infant | 26 | 2023 | 35070 | 0.250 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 281 | 0.250 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4229 | 0.250 |
Why?
|
DNA-Binding Proteins | 4 | 2022 | 9639 | 0.240 |
Why?
|
Fireflies | 1 | 2023 | 3 | 0.240 |
Why?
|
Pineal Gland | 2 | 2019 | 165 | 0.240 |
Why?
|
Combined Modality Therapy | 9 | 2023 | 8621 | 0.230 |
Why?
|
Radiotherapy | 3 | 2008 | 1525 | 0.230 |
Why?
|
Transplantation, Autologous | 4 | 2022 | 2123 | 0.220 |
Why?
|
Neoplasms | 8 | 2024 | 21596 | 0.220 |
Why?
|
Choriocarcinoma | 1 | 2022 | 123 | 0.210 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13655 | 0.210 |
Why?
|
Autopsy | 2 | 2019 | 1006 | 0.210 |
Why?
|
Disease-Free Survival | 9 | 2017 | 6891 | 0.200 |
Why?
|
Neurology | 1 | 2009 | 762 | 0.200 |
Why?
|
Molecular Targeted Therapy | 5 | 2022 | 2723 | 0.200 |
Why?
|
Humans | 82 | 2024 | 742088 | 0.190 |
Why?
|
Sarcoma | 2 | 2022 | 1895 | 0.190 |
Why?
|
Stem Cell Transplantation | 2 | 2006 | 1618 | 0.180 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2020 | 45 | 0.180 |
Why?
|
Astrocytoma | 2 | 2017 | 789 | 0.180 |
Why?
|
Glioblastoma | 3 | 2023 | 3456 | 0.180 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2018 | 13 | 0.170 |
Why?
|
Craniopharyngioma | 2 | 2012 | 281 | 0.170 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3691 | 0.170 |
Why?
|
Mutation | 10 | 2022 | 29717 | 0.160 |
Why?
|
Prognosis | 16 | 2022 | 29010 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 123 | 0.160 |
Why?
|
DNA Helicases | 1 | 2023 | 861 | 0.160 |
Why?
|
Osteosarcoma | 1 | 2004 | 880 | 0.160 |
Why?
|
Benzamides | 1 | 2023 | 1378 | 0.160 |
Why?
|
Metabolic Clearance Rate | 1 | 2018 | 379 | 0.150 |
Why?
|
Quinazolines | 2 | 2015 | 1355 | 0.150 |
Why?
|
Etoposide | 4 | 2023 | 637 | 0.150 |
Why?
|
Antigens, Neoplasm | 2 | 2002 | 1983 | 0.150 |
Why?
|
Neurofibromatosis 1 | 2 | 2020 | 562 | 0.140 |
Why?
|
Neurocytoma | 1 | 2016 | 30 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2019 | 295 | 0.140 |
Why?
|
Emigrants and Immigrants | 1 | 2022 | 519 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5522 | 0.130 |
Why?
|
Angiogenesis Inhibitors | 3 | 2013 | 2038 | 0.120 |
Why?
|
Male | 39 | 2023 | 349538 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2028 | 0.120 |
Why?
|
Young Adult | 16 | 2022 | 56350 | 0.120 |
Why?
|
Pediatrics | 1 | 2009 | 3462 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1606 | 0.120 |
Why?
|
Survivors | 3 | 2024 | 2286 | 0.120 |
Why?
|
Hematologic Diseases | 1 | 2018 | 498 | 0.120 |
Why?
|
Histones | 2 | 2022 | 2597 | 0.120 |
Why?
|
Female | 39 | 2023 | 379592 | 0.120 |
Why?
|
Transcription Factors | 3 | 2023 | 12164 | 0.120 |
Why?
|
Treatment Failure | 2 | 2018 | 2615 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2020 | 1269 | 0.120 |
Why?
|
Vaccines | 1 | 2022 | 817 | 0.110 |
Why?
|
Child Mortality | 1 | 2015 | 198 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2019 | 490 | 0.110 |
Why?
|
Cancer Vaccines | 1 | 2020 | 1021 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10943 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1333 | 0.110 |
Why?
|
Diabetes Insipidus | 1 | 2013 | 151 | 0.110 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2012 | 43 | 0.100 |
Why?
|
Pituitary Diseases | 1 | 2013 | 141 | 0.100 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39004 | 0.100 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2522 | 0.100 |
Why?
|
Genes, cdc | 1 | 2011 | 116 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 6534 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2020 | 2556 | 0.100 |
Why?
|
Repressor Proteins | 1 | 2002 | 3020 | 0.100 |
Why?
|
Retrospective Studies | 18 | 2023 | 77098 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2016 | 5425 | 0.100 |
Why?
|
Infant Mortality | 1 | 2015 | 754 | 0.090 |
Why?
|
Skin Diseases | 1 | 2019 | 1065 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 665 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 13 | 0.090 |
Why?
|
Flow Cytometry | 1 | 2020 | 5975 | 0.090 |
Why?
|
Neovascularization, Pathologic | 2 | 2013 | 2633 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1167 | 0.090 |
Why?
|
Intracranial Hypertension | 1 | 2012 | 186 | 0.090 |
Why?
|
Survival Rate | 8 | 2017 | 12773 | 0.090 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 883 | 0.090 |
Why?
|
Pons | 1 | 2010 | 245 | 0.090 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 1940 | 0.080 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2008 | 61 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5851 | 0.080 |
Why?
|
Treatment Outcome | 11 | 2020 | 62966 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1548 | 0.080 |
Why?
|
Infratentorial Neoplasms | 1 | 2008 | 94 | 0.080 |
Why?
|
Pinealoma | 1 | 2008 | 54 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 35342 | 0.080 |
Why?
|
Adult | 19 | 2024 | 213712 | 0.080 |
Why?
|
Medical Records | 1 | 2013 | 1413 | 0.080 |
Why?
|
Supratentorial Neoplasms | 1 | 2008 | 160 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4438 | 0.070 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2236 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2012 | 1184 | 0.070 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1758 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1241 | 0.070 |
Why?
|
Vincristine | 2 | 2007 | 1036 | 0.070 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2008 | 472 | 0.070 |
Why?
|
Thalidomide | 2 | 2013 | 888 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3444 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5163 | 0.070 |
Why?
|
Mesna | 1 | 2004 | 66 | 0.060 |
Why?
|
Cerebral Arteries | 1 | 2007 | 492 | 0.060 |
Why?
|
Genomics | 2 | 2017 | 5692 | 0.060 |
Why?
|
Intelligence | 1 | 2009 | 920 | 0.060 |
Why?
|
Moyamoya Disease | 1 | 2007 | 237 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1659 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4414 | 0.060 |
Why?
|
Leucovorin | 1 | 2004 | 624 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2013 | 2410 | 0.050 |
Why?
|
Gene Dosage | 3 | 2017 | 1251 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3639 | 0.050 |
Why?
|
United States | 3 | 2023 | 69693 | 0.050 |
Why?
|
Cisplatin | 2 | 2007 | 1637 | 0.050 |
Why?
|
Administration, Oral | 3 | 2018 | 3913 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3585 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2019 | 2638 | 0.050 |
Why?
|
Methotrexate | 2 | 2007 | 1720 | 0.050 |
Why?
|
Central Nervous System | 2 | 2022 | 1354 | 0.050 |
Why?
|
Remission Induction | 2 | 2005 | 2384 | 0.050 |
Why?
|
Feasibility Studies | 4 | 2018 | 5062 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2107 | 0.050 |
Why?
|
Bone Marrow | 2 | 2002 | 2941 | 0.050 |
Why?
|
Camptothecin | 2 | 2017 | 572 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2527 | 0.050 |
Why?
|
Ribonuclease III | 1 | 2022 | 275 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 380 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 647 | 0.040 |
Why?
|
Radiation Injuries | 1 | 2007 | 1178 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11001 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2004 | 13019 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 375 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2005 | 3471 | 0.040 |
Why?
|
Contrast Media | 1 | 2012 | 5295 | 0.040 |
Why?
|
Thymidine Kinase | 1 | 2019 | 290 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 2935 | 0.040 |
Why?
|
Basal Ganglia | 1 | 2021 | 545 | 0.040 |
Why?
|
Japan | 1 | 2022 | 1360 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 800 | 0.040 |
Why?
|
Oximes | 1 | 2019 | 309 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4801 | 0.040 |
Why?
|
Prodrugs | 1 | 2019 | 268 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 424 | 0.040 |
Why?
|
Cognition | 2 | 2016 | 6722 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12958 | 0.040 |
Why?
|
Prospective Studies | 5 | 2018 | 53187 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 2215 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1263 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 627 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 1792 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 496 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2016 | 203 | 0.030 |
Why?
|
Thalamus | 1 | 2021 | 1023 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4751 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2085 | 0.030 |
Why?
|
Epigenomics | 1 | 2020 | 902 | 0.030 |
Why?
|
Adenoviridae | 1 | 2019 | 1096 | 0.030 |
Why?
|
Biological Availability | 1 | 2015 | 396 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2876 | 0.030 |
Why?
|
Animals | 6 | 2023 | 168561 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17400 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 849 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2022 | 25575 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10248 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2001 | 1376 | 0.030 |
Why?
|
Incidence | 3 | 2022 | 20928 | 0.030 |
Why?
|
Fenofibrate | 1 | 2013 | 88 | 0.030 |
Why?
|
Sirolimus | 1 | 2020 | 1562 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6756 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3587 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1767 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2004 | 2721 | 0.030 |
Why?
|
Imidazoles | 1 | 2019 | 1205 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 23387 | 0.030 |
Why?
|
Quality of Life | 2 | 2024 | 12730 | 0.030 |
Why?
|
Hearing | 1 | 2016 | 479 | 0.030 |
Why?
|
Mice, Nude | 1 | 2019 | 3689 | 0.030 |
Why?
|
SEER Program | 1 | 2017 | 1507 | 0.030 |
Why?
|
Mice | 4 | 2023 | 81045 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14720 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2948 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
Recurrence | 1 | 2023 | 8333 | 0.030 |
Why?
|
Viral Proteins | 1 | 2019 | 1899 | 0.020 |
Why?
|
Alleles | 2 | 2019 | 6931 | 0.020 |
Why?
|
Disease Progression | 2 | 2005 | 13256 | 0.020 |
Why?
|
Kidney | 2 | 2019 | 7167 | 0.020 |
Why?
|
Zebrafish | 1 | 2022 | 2990 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2011 | 0.020 |
Why?
|
Time Factors | 4 | 2015 | 40054 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 6974 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8297 | 0.020 |
Why?
|
Cell Cycle | 1 | 2019 | 2964 | 0.020 |
Why?
|
RNA Interference | 1 | 2019 | 2890 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 222 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4553 | 0.020 |
Why?
|
Risk Factors | 4 | 2015 | 72145 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 16665 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7790 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3420 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1839 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20086 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2372 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9410 | 0.020 |
Why?
|
Boston | 2 | 2014 | 9305 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2253 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 7901 | 0.020 |
Why?
|
Thiotepa | 1 | 2007 | 66 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2012 | 1097 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2011 | 701 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1807 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 544 | 0.020 |
Why?
|
Circle of Willis | 1 | 2007 | 68 | 0.020 |
Why?
|
Gene Amplification | 1 | 2011 | 1062 | 0.020 |
Why?
|
Optic Chiasm | 1 | 2007 | 87 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4420 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8077 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2019 | 2978 | 0.020 |
Why?
|
Oncogenes | 1 | 2012 | 1263 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9144 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 692 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5304 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1772 | 0.020 |
Why?
|
Age Factors | 2 | 2015 | 18355 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
Endostatins | 1 | 2005 | 174 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 15494 | 0.020 |
Why?
|
Cause of Death | 1 | 2015 | 3571 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2203 | 0.020 |
Why?
|
Thrombospondins | 1 | 2005 | 197 | 0.020 |
Why?
|
Drug Therapy | 1 | 2008 | 497 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1361 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 2842 | 0.010 |
Why?
|
Carboplatin | 1 | 2007 | 799 | 0.010 |
Why?
|
Sulfonamides | 1 | 2013 | 1932 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3439 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8425 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3306 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2005 | 599 | 0.010 |
Why?
|
Pyrazoles | 1 | 2013 | 1970 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5872 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2008 | 1363 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16331 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 7010 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2008 | 11363 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1520 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1434 | 0.010 |
Why?
|
Ploidies | 1 | 2001 | 281 | 0.010 |
Why?
|
S100 Proteins | 1 | 2001 | 259 | 0.010 |
Why?
|
Gangliosides | 1 | 2001 | 140 | 0.010 |
Why?
|
Schwann Cells | 1 | 2001 | 195 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5212 | 0.010 |
Why?
|
Genes, myc | 1 | 2001 | 399 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1769 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6259 | 0.010 |
Why?
|
Phosphorylation | 1 | 2010 | 8436 | 0.010 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2010 | 2736 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 24913 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15056 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 2002 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 19223 | 0.010 |
Why?
|
Stromal Cells | 1 | 2001 | 1353 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2000 | 974 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3502 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23320 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.010 |
Why?
|
Cohort Studies | 1 | 2016 | 40450 | 0.010 |
Why?
|
Comorbidity | 1 | 2007 | 10372 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12220 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12705 | 0.010 |
Why?
|